A multiomic classification of NDMM linked to Isa-KRd response is defined, with a multimodal random forest model outperforming clinical and genomic models and providing comparable discrimination and improved calibration relative to the transcriptomic and epigenomic models.
F. Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit et al.· Nature Medicine· 0 citations
SC forimtamig demonstrated potent and durable activity in RRMM, which could be enhanced with a condensed step-up schedule, highlighting the narrow therapeutic window for GPRC5D as a target for T-cell-engaging bispecific antibodies.
Anna Caroline Hasselbalch, Simon J. Harrison, Salomon Manier et al.· Blood Advances· 0 citations
In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in transplant-ineligible newly diagnosed multiple myelom...
T. Facon, G. Cook, S. Usmani et al.· Leukemia· 0 citations
The phase III CEPHEUS trial (ClinicalTrials.gov identifier: NCT03652064) of patients with transplant-ineligible (TIE) or transplant-deferred newly diagnosed multiple myeloma (NDMM; N = 395) demonstrated improved overall minimal residual disease (MRD) negativity rates among patients achieving ≥complete response and prog...
S. Usmani, T. Facon, V. Hungria et al.· Journal of Clinical Oncology· 0 citations
OBJECTIVES
B-cell maturation antigen (BCMA)-targeted therapies have recently transformed the management of relapsed or refractory multiple myeloma (RRMM). This study aimed to evaluate their implementation and real-world impact within EMMY, a French longitudinal cohort.
METHODS
Patients initiating a fourth or later li...
T. Cazaubiel, O. Decaux, A. Perrot et al.· European Journal of Haematol...· 0 citations
T-cell bispecific (TCB) therapies have demonstrated promising therapeutic efficacies for patients with relapsed/refractory multiple myeloma. However, responses are transient and essentially all patients eventually relapse. Cytokine release syndrome and other on-target off-tumor toxicities are common. Together, these ch...
I. Dekhtiarenko, Jan Attig, I. Lelios et al.· Blood Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
